Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

The Proteasome02:18

The Proteasome

10.0K
Eukaryotic cells can degrade proteins through several pathways. One of the most important amongst these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
10.0K
The Proteasome01:13

The Proteasome

1.6K
Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
1.6K
The Proteasome02:18

The Proteasome

4.4K
4.4K
Regulated Protein Degradation02:58

Regulated Protein Degradation

8.7K
It is vital to regulate the activity of enzymatic as well as non-enzymatic proteins inside the cell. This can be achieved either through creating a balance between their rate of synthesis and degradation or regulating the intrinsic activity of the protein. Both these regulation mechanisms play an essential role in the normal functioning of cells.
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
8.7K
Regulated Protein Degradation02:58

Regulated Protein Degradation

3.1K
3.1K
T Cell Types and Functions01:24

T Cell Types and Functions

2.1K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
2.1K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Sulfur dioxide delays quality deterioration by maintaining energy metabolism and mitochondrial structure in postharvest table grapes.

Journal of the science of food and agriculture·2026
Same author

Recent progresses in cancer multidrug resistance and therapeutic options associated with protein damage response.

Protein & cell·2026
Same author

Pathology-based thermal ablation safety margin for follicular adenoma: a digital whole-slide study of follicular carcinoma invasion.

Frontiers in endocrinology·2026
Same author

Survival benefit of adjuvant radiotherapy for gallbladder cancer patients with stage IIIA: a population based, propensity score-matched study.

Translational cancer research·2026
Same author

Clinical Implications of Serum Matrix Metalloproteinase-12 and Tumor Cadherin-13 for Molecular Subtyping and Personalized Therapy in Lung Cancer.

Journal of visualized experiments : JoVE·2026
Same author

Predicting Multidrug-Resistant Pneumonia: An Interpretable Machine Learning Model Validated in US and Chinese Patient Cohorts.

Infection and drug resistance·2026

相关实验视频

Updated: Jan 10, 2026

Assaying Proteasomal Degradation in a Cell-free System in Plants
07:43

Assaying Proteasomal Degradation in a Cell-free System in Plants

Published on: March 26, 2014

15.0K

蛋白质组:T细胞功能调节中的作用

Dongyang Tang1,2, Xiaoran Wu1,2, Josh Haipeng Lei1,2

  • 1Cancer Center, Faculty of Health Sciences, University of Macau, Macau SAR, China.

International journal of biological sciences
|November 24, 2025
PubMed
概括
此摘要是机器生成的。

蛋白质酶抑制剂在液体癌症中是有效的,但不是固体瘤. 了解它们在T细胞免疫中的作用可能会解锁新的癌症免疫疗法策略.

关键词:
抗瘤免疫力 抗瘤免疫力自身免疫性疾病 自身免疫性疾病蛋白质酶体蛋白质组是什么蛋白质酶体抑制剂 蛋白质酶体抑制剂

更多相关视频

Multicolor Flow Cytometry-based Quantification of Mitochondria and Lysosomes in T Cells
06:22

Multicolor Flow Cytometry-based Quantification of Mitochondria and Lysosomes in T Cells

Published on: January 9, 2019

13.7K
Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

9.5K

相关实验视频

Last Updated: Jan 10, 2026

Assaying Proteasomal Degradation in a Cell-free System in Plants
07:43

Assaying Proteasomal Degradation in a Cell-free System in Plants

Published on: March 26, 2014

15.0K
Multicolor Flow Cytometry-based Quantification of Mitochondria and Lysosomes in T Cells
06:22

Multicolor Flow Cytometry-based Quantification of Mitochondria and Lysosomes in T Cells

Published on: January 9, 2019

13.7K
Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

9.5K

科学领域:

  • 免疫学 免疫学 免疫学
  • 细胞生物学 细胞生物学
  • 癌症研究 癌症研究

背景情况:

  • 蛋白质酶对蛋白质稳态和细胞功能至关重要.
  • 目前的蛋白酶体抑制剂在液体癌症中显示出有效性,但在固体瘤中成功程度有限.
  • 新出现的证据强调了蛋白质酶在蛋白质降解之外的T细胞功能中的作用.

研究的目的:

  • 审查蛋白质酶活性在T细胞生物学中的多方面的作用.
  • 探索蛋白质酶抑制剂对T细胞介导的抗瘤免疫的影响.
  • 通过使用蛋白酶体抑制剂来确定固体癌症和自身免疫性疾病的新型治疗策略.

主要方法:

  • 文献综述总结了关于T细胞中蛋白质酶功能的当前知识.
  • 探索蛋白质酶对T细胞选择,衰老,激活,分化和免疫逃避的影响.
  • 讨论新兴技术,如CRISPR编辑,单细胞蛋白质组学和人工智能驱动的药物设计.

主要成果:

  • 蛋白质组显著影响T细胞命运,包括抗原处理,代谢重编程和预防疲劳.
  • 蛋白质酶抑制剂可以调节T细胞介导的抗瘤免疫力,这可能解释了它们在各种癌症中的差异性疗效.
  • 了解这些机制为克服固体瘤抵抗提供了洞察力.

结论:

  • 蛋白酶体在T细胞免疫中的作用对于其在癌症中的治疗潜力至关重要.
  • 向蛋白酶体为开发用于固体瘤的新型免疫疗法提供了有希望的途径.
  • 先进的技术可能会扩大蛋白酶体抑制剂在治疗癌症和自身免疫性疾病中的应用.